Nerium Biotechnology Reports Restated Financial Results
(firmenpresse) - SAN ANTONIO, TEXAS -- (Marketwired) -- 12/01/14 -- Nerium Biotechnology, Inc. (the "Company"), announced today that, due to a mathematical formula error in its equity investment calculations, it has restated its consolidated balance sheets as at September 30, 2013; December 31, 2013; March 31, 2014 and June 30, 2014 and its consolidated statements of income and comprehensive income for the three-month and nine-month periods ended September 30, 2013; the year ended December 31, 2013; the three-month period ended March 31, 2014; and the three-month and six-month periods ended June 30, 2014. There was no significant impact on the cash flows of the Company as these adjustments represent non-cash items.
Restatement of Documents
The Company intends to include the effect of this restatement, where applicable, in its interim condensed consolidated financial statements for September 30, 2014 to be filed with the Canadian securities regulators and available for review at . The SEDAR filing also will include a related management''s discussion and analysis.
Impact of the Restatement
The following tables summarize the corrections on each of the affected consolidated financial statement line items presented in the respective financial statements:
About Nerium Biotechnology, Inc.
Nerium Biotechnology, Inc. is a biotechnology company involved in the research, product development, manufacture and marketing of Nerium oleander-based products. The Company''s shares are not listed on any stock exchange or quotation system.
Contacts:
Nerium Biotechnology, Inc.
Joseph B. Nester
CFO
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.12.2014 - 17:48 Uhr
Sprache: Deutsch
News-ID 1322155
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN ANTONIO, TEXAS
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 145 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nerium Biotechnology Reports Restated Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Nerium Biotechnology, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
